Koneksa Appoints Eric Luthi as Chief Business Officer

Koneksa Appoints Eric Luthi as Chief Business Officer

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today the appointment of Eric Luthi as Chief Business Officer. In this newly created role, Mr. Luthi brings over 25 years of experience in life sciences an

d will lead corporate and business development initiatives at Koneksa.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241111234631/en/

Eric Luthi, Chief Business Officer, Koneksa (Photo credit: Koneksa)

“We’re thrilled to welcome Eric to lead our business development team,” said Chris Benko, CEO and Co-Founder of Koneksa. “With his extensive industry expertise and proven success in driving growth and strategy, Eric will play a pivotal role in advancing our strategic initiatives and forming essential partnerships with leading healthcare organizations. His leadership will be invaluable as we empower biopharma companies to utilize digital biomarkers to accelerate clinical trials and unlock critical data insights.”

“I’m honored to join Koneksa as we continue to advance the role of evidence-based digital biomarkers in clinical trials to accelerate decision making and improve patient outcomes,” said Eric Luthi, Chief Business Officer, Koneksa. “Our commitment to leveraging advanced technology and real-time data streaming for data-driven insights is unparalleled. Our recent data syndication efforts encourage pre-competitive collaboration among companies to validate novel digital endpoints to provide baseline disease metrics in Parkinson’s disease. This approach not only benefits our partners but also supports improved patient outcomes. I’m excited to expand these partnerships and drive similar initiatives across additional therapeutic areas.”

Prior to joining Koneksa, Mr. Luthi served as Chief Commercial Officer at Evergreen Therapeutics, where he established the commercial function and led the development of the launch strategy for the company’s diagnostic radiopharmaceutical.

Eric has held commercial leadership roles in large and small pharmaceutical companies in the US, Canada, and Switzerland. Over his 20-year tenure at Merck & Co., Inc., Eric helped to integrate research and commercial strategies in a number of key therapeutic areas for the company and, working closely with R&D leadership, was the commercial lead for cardiovascular products in clinical development. As head of Digital and Commercial Operations for Merck’s subsidiary in Canada, he was responsible for enhancing customer engagement and driving revenue growth by integrating digital and traditional marketing efforts. He holds a Bachelor of Science degree with a double major in Biology and Psychology from Muhlenberg College.

About Koneksa

Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. Our evidence-based biomarker solutions enable efficient clinical trial designs to help innovative therapies reach patients faster. Koneksa aims to revolutionize treatment effect detection in clinical research and improve patient outcomes. Learn more at koneksahealth.com.